CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $15.17M, lower than 95% of all stocks globally
- PositionGross margin is -200.7%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.78BTWD306.41M · vs all stocks (USD)
Revenue (TTM)
483.94MTWD15.17M · vs all stocks (USD)
Profit Margin
-294.08%vs Biotechnology peers
Beta
0.2150xvs all stocks
52-Week Change
-35.18%vs all stocks
Market Capitalization
9.78BTWD306.41M · vs all stocks (USD)
Enterprise Value
10.64BTWD333.45M · vs all stocks (USD)
Forward P/E
-9.41xvs Biotechnology peers
Price to Sales (TTM)
19.27xvs Biotechnology peers
Price to Book (MRQ)
1.74xvs Biotechnology peers
Enterprise to Revenue
21.99xvs Biotechnology peers
Enterprise to EBITDA
-8.56xvs Biotechnology peers
Gross Margin
-200.66%vs Biotechnology peers
Profit Margin
-294.08%vs Biotechnology peers
Operating Margin
-301.32%vs Biotechnology peers
Return on Assets (TTM)
-11.28%vs Biotechnology peers
Return on Equity (TTM)
-26.08%vs Biotechnology peers
Revenue (TTM)
483.94MTWD15.17M · vs all stocks (USD)
Revenue per Share (TTM)
1.89TWDUpdated Aug 21, 2026Quarterly Revenue Growth
166.40%vs Biotechnology peers
Gross Profit (TTM)
-685.21MTWD-21.47M · vs all stocks (USD)
EBITDA (TTM)
-1.24BTWD-38.94M · vs all stocks (USD)
Net Income (TTM)
-1.42BTWD-44.60M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
166.39%vs Biotechnology peers
Operating Cash Flow (TTM)
-1.03BTWD-32.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.43BTWD-44.84M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
400.97MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
841.68MTWDFY2025 · Dec 31, 2025Gross Profit
-440.71MTWDFY2025 · Dec 31, 2025Operating Income
-1.38BTWD-43.30M · vs all stocks (USD)
Pre-tax Income
-1.50BTWDFY2025 · Dec 31, 2025Income Tax Expense
-3.05MTWDFY2025 · Dec 31, 2025Net Income
-1.50BTWDFY2025 · Dec 31, 2025EBIT
-1.46BTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.08BTWDFY2025 · Dec 31, 2025Research & Development
510.82MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
430.19MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
39.88MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
47.23MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-1.56BTWDFY2025 · Dec 31, 2025Free Cash Flow
-2.21BTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
878.71MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.50BTWDFY2025 · Dec 31, 2025Stock-based Compensation
9.07MTWDFY2025 · Dec 31, 2025Other Non-cash Items
8.27MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
161.97MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-231.76MTWDFY2025 · Dec 31, 2025Capital Expenditures
-655.35MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.94MTWDFY2025 · Dec 31, 2025Net Acquisitions
1.00BTWDFY2025 · Dec 31, 2025Purchase of Investments
-300.00KTWDFY2025 · Dec 31, 2025Sale of Investments
5.30MTWDFY2025 · Dec 31, 2025Other Investing Activity
-50.16MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
303.75MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00TWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
30.00MTWDFY2025 · Dec 31, 2025Other Financing Charges
222.00KTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
1.29BTWDFY2025 · Dec 31, 2025Shares Outstanding
264.99MSharesUpdated Aug 21, 2026Float Shares
108.18MSharesUpdated Aug 21, 2026% Held by Insiders
61.93%vs all stocks
% Held by Institutions
0.07%vs all stocks
Total Cash (MRQ)
442.24MTWD13.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.67TWDUpdated Aug 21, 2026Total Debt (MRQ)
1.68BTWD52.53M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3125xvs Biotechnology peers
Current Ratio (MRQ)
1.33xvs Biotechnology peers
Book Value per Share (MRQ)
20.24TWDUpdated Aug 21, 2026Total Assets
7.96BTWD249.48M · vs all stocks (USD)
Total Current Assets
1.50BTWDFY2025 · Dec 31, 2025Total Liabilities
2.27BTWDFY2025 · Dec 31, 2025Total Non-current Assets
6.46BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.47BTWDFY2025 · Dec 31, 2025Total Current Liabilities
799.66MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
878.71MTWDFY2025 · Dec 31, 2025Accounts Receivable
30.20MTWDFY2025 · Dec 31, 2025Inventory
416.48MTWDFY2025 · Dec 31, 2025Accounts Payable
102.98MTWDFY2025 · Dec 31, 2025Short-term Debt
211.63MTWDFY2025 · Dec 31, 2025Other Current Liabilities
819.00KTWDFY2025 · Dec 31, 2025Long-term Debt
1.37BTWDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.72MTWDFY2025 · Dec 31, 2025Common Stock (Book)
2.65BTWDFY2025 · Dec 31, 2025Retained Earnings
-15.64BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
5.69BTWD178.43M · vs all stocks (USD)
52-Week Low
34.85TWDUpdated Aug 21, 202652-Week High
68.00TWDUpdated Aug 21, 202652-Week Change
-35.18%vs all stocks
Beta
0.2150xvs all stocks
50-Day MA
39.58TWDUpdated Aug 21, 2026200-Day MA
45.84TWDUpdated Aug 21, 2026Avg 10-Day Volume
273.31KSharesUpdated Aug 21, 2026Avg 30-Day Volume
323.05KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-5.51TWDUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -200.7%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -2.01Industry median: 0.67Industry P5: 0.14Peers compared: 261
Financial Health
Altman Z-Score -0.61: distress zoneCritical
Altman Z-Score: -0.61
High structural barrier to entryNotable
Barrier to Entry: 172.477
Consistent revenue growth patternNotable
Growth Consistency Score: 0.94
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $15.17M, lower than 95% of all stocks globallySignificant
Revenue (USD): 15,165,102.432Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule